Table 2 Comparison of therapeutic efficacy between polymyxin B and colistin sulfate groups
Polymyxin B (N = 68) | Colistin sulfate (N = 36) | P.value | |
|---|---|---|---|
Primary Outcome | |||
Clinical success on day 7 | 23 (33.8%) | 15 (41.7%) | 0.429 |
Microbial success | 16 (30.8%),n = 52 | 16 (57.1%),n = 28 | 0.022 |
Secondary Outcome | |||
Inflammation index on day 7 | |||
WBCa count returned to normal | 46 (67.6%) | 20 (55.6%) | 0.223 |
Neutrophils returned to normal | 24 (35.3%) | 13 (36.1%) | 0.934 |
CRPb returned to normal | 10 (14.7%) | 5 (13.9%) | 0.910 |
SAAc returned to normal | 11 (16.2%) | 7 (19.4%) | 0.675 |
Variation of WBC(*109/L) Median (Min, Max) | 5.02 (-15.00, 20.00),n = 22 | 4.02 (-0.790, 50.6),n = 16 | 0.827 |
Variation of neutrophil (%)Mean (± SD) | 5.45 (± 5.89),n = 44 | 6.30 (± 4.63),n = 23 | 0.518 |
Variation of CRP (mg/L) Median (Min, Max) | 52.80 (-30.40, 197.00),n = 58 | 67.1 (2.90, 195),n = 31 | 0.399 |
Variation of SAA (mg/L) Median (Min, Max) | 90.70(-341.00, 509.00),n = 57 | 28.3 (-471, 533),n = 29 | 0.369 |
Defervescence at day 7 | 45(95.6%),n = 48 | 17 (89.5%),n = 19 | 0.617 |
Time to defervescence (d) Median (Min, Max) | 2.00 (1.00, 7.00),n = 45 | 2.00 (1.00, 3.00),n = 17 | 0.212 |
Imaging remission on day 7 | 26 (51.0%),n = 51 | 16(55.2%),n = 29 | 0.718 |
Reinfection of other CR-GNBd | 7 (10.3%) | 4 (11.1%) | 1.000 |
Length of hospital stay (d) Median (Min, Max) | 13.00(3.00, 61.00) | 14.0 (3.00, 44.0) | 0.905 |
14-day mortality | 21 (30.9%) | 9 (25.0%) | 0.529 |
28-day mortality | 27 (39.7%) | 12 (33.3%) | 0.523 |
Total mortality | 27 (39.7%) | 12 (33.3%) | 0.523 |